The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3&bgr) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders (ii) neurodegenerative diseases (iii) mood disorders (iv) schizophrenic disorders (v) cancerous disorders (vi) inflammation, (vii) substance abuse disorders (viii) epilepsies and (ix) neuropathic pain.
